(Booth 9157) French computer-aided detection (CAD) software developer Median Technologies of Sophia Antipolis will demonstrate its progress in commercializing its Lesion Management Solution (LMS) line of software.
Median said it has launched the product line in Europe and opened a sales office in Minneapolis to direct U.S. activities. It is also pursuing partnerships with academic centers to foster cooperation between radiologists and oncologists.
Median said that the LMS software is designed to automate the tasks that radiologists normally carry out manually. LMS applications generate reports according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria used to evaluate the treatment response of solid tumors. The software can also be integrated with PACS or RIS networks.
Median is also developing LMS-Colon, which does not yet have FDA clearance and will be shown as a work-in-progress for CT colonography applications.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
